Literature DB >> 19694945

Heparin but not citrate anticoagulation of blood preserves platelet function for prolonged periods.

N J Truss1, P C J Armstrong, E Liverani, I Vojnovic, T D Warner.   

Abstract

BACKGROUND: Current guidelines state that platelet aggregation studies should be conducted within 4 h of venepuncture because of the decline in sensitivity to platelet agonists. This constrains studies of platelet activity in clinical situations where samples need to be transported or there are unavoidable delays prior to assessment.
OBJECTIVES: The aim of the present study was to compare systematically the responses of platelets stored in the presence of either citrate or heparin, the two most widely used anti-coagulants, using a range of standard techniques.
METHODS: Blood was taken from healthy volunteers and either assessed immediately or stored at ambient temperature (18-25 degrees C) for 24 h. Platelet reactivity to a range of agonists was determined by a combination of 96-well plate techniques; light transmission aggregometry, thrombi adhesion, ATP and ADP release, and TxA(2) release; by whole blood aggregometry; and by PFA-100. RESULTS AND
CONCLUSIONS: Testing using 96-well plate techniques allowed for the simultaneous measurement of responses to multiple concentrations of multiple agonists. The responses of platelets from blood anti-coagulated with heparin were predominantly preserved in all assays after 24 h storage, whereas, responses of platelets stored in blood anti-coagulated with citrate were greatly diminished. Consequently, anti-coagulation with heparin, but not citrate, preserves platelet responses for up to 24 h as determined by a range of techniques.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19694945     DOI: 10.1111/j.1538-7836.2009.03589.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  5 in total

1.  Assessment of platelet function by whole blood impedance aggregometry in coronary artery bypass grafting patients on acetylsalicylic acid treatment may prompt a switch to dual antiplatelet therapy.

Authors:  Mate Petricevic; Bojan Biocina; Sanja Konosic; Tomislav Kopjar; Nino Kunac; Hrvoje Gasparovic
Journal:  Heart Vessels       Date:  2011-12-28       Impact factor: 2.037

2.  Assessment of Multiplate platelet aggregometry using citrate, heparin or hirudin in Rhesus macaques.

Authors:  Greg Dugan; Lisa O'Donnell; David B Hanbury; J Mark Cline; David L Caudell
Journal:  Platelets       Date:  2014-12-30       Impact factor: 3.862

3.  Thrombospondin-1 protects against pathogen-induced lung injury by limiting extracellular matrix proteolysis.

Authors:  Yanyan Qu; Tolani Olonisakin; William Bain; Jill Zupetic; Rebecca Brown; Mei Hulver; Zeyu Xiong; Jesus Tejero; Robert Mq Shanks; Jennifer M Bomberger; Vaughn S Cooper; Michael E Zegans; Hyunryul Ryu; Jongyoon Han; Joseph Pilewski; Anuradha Ray; Zhenyu Cheng; Prabir Ray; Janet S Lee
Journal:  JCI Insight       Date:  2018-02-08

4.  In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation.

Authors:  P C J Armstrong; P D Leadbeater; M V Chan; N S Kirkby; J A Jakubowski; J A Mitchell; T D Warner
Journal:  J Thromb Haemost       Date:  2011-03       Impact factor: 5.824

5.  Dual antiplatelet therapy in patients with aspirin resistance following coronary artery bypass grafting: study protocol for a randomized controlled trial [NCT01159639].

Authors:  Hrvoje Gasparovic; Mate Petricevic; Tomislav Kopjar; Zeljko Djuric; Lucija Svetina; Bojan Biocina
Journal:  Trials       Date:  2012-08-25       Impact factor: 2.279

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.